Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by EternalPonzion Feb 13, 2020 3:03pm

120 Views

Post# 30687457

RE:RE:RE:RE:RE:FYI - George W. Haywood - SCHEDULE 13G - February 13, 2020

Thanks for that postie. Why reduce your position to such an extent for a company arguably at the cusp of making a breakthrough? The posters on this board who suspected something smells when all that unusual trading activity was happening 23-24 Dec were bang on. It's time to file an SEC insider trading complaint. I looked at the form. It seems fairly straightforward. The more people that do it the more likely this will actually be investigated.

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!